Stoke Therapeutics Inc is a biotechnology company that develops treatments for genetic diseases. The Company develops antisense oligonucleotide medicines that target ribo-nucleic acid (RNA) splicing to increase gene expression for the treatment of severe genetic diseases. It uses targeted augmentation of nuclear gene output (TANGO) to effect targeted enhancement of gene expression. It provides TANGO, which is a precision medicine platform for treating a category of genetic diseases, such as autosomal dominant haploinsufficiency. TANGO is designed to address protein deficiency by upregulating target protein expression.